Reuters logo
BRIEF-Northwest Biotherapeutics provides update about phase 3 trial of Dcvax-L
December 8, 2016 / 7:16 PM / a year ago

BRIEF-Northwest Biotherapeutics provides update about phase 3 trial of Dcvax-L

Dec 8 (Reuters) - Northwest Biotherapeutics Inc:

* NW Bio provides update about phase 3 trial of Dcvax-L for newly diagnosed glioblastoma multiforme brain cancer

* Company announced that 331 of planned 348 patients have been enrolled in phase 3 trial of Dcvax-L

* As a result of partial hold, trial has not enrolled last 17 of total 348 patients

* Since summer of last year, trial has been subject to a partial clinical hold, only on recruitment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below